Stamford Hospital, Stamford, Connecticut; Magee-Women's Hospital, Pittsburgh, Pennsylvania; Arizona Gynecology Consultants, Phoenix, Arizona; Mercy Hospital, St. Louis, Missouri; Virginia Mason Medical Center, Seattle, Washington; and Hospital Universitario “Dr. José Eleuterio González” de Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico.
Corresponding author: Scott Chudnoff, MD, Department of Obstetrics and Gynecology, Stamford Hospital, Whittingham Pavilion, Ground Floor, 1 Hospital Plaza, Stamford, CT 06902; email: [email protected].
The institutions involved in this study received research support from Gynesonics, Inc.
Financial Disclosure Scott Chudnoff, Richard Guido, Linda Mihalov, and José Gerardo Garza-Leal have served on the Gynesonics, Inc, advisory board. Scott Chudnoff received travel and lodging expenses for attendance at an investigator meeting and has received honoraria for speaking from Gynesonics, Inc. Kelly Roy has received royalties from CrossBay Medical, Inc. and stock options from Channel Medical, Inc, and has served as a consultant for Boston Scientific, Inc. David Levine has been a consultant for Gynesonics and a consultant for Aegea Medical. Linda Mihalov has also served on the advisory board for Abbvie. José Gerardo Garza-Leal has received a stock option grant from Gynesonics, Inc. Scott Chudnoff, Richard Guido, Kelly Roy, David Levine, and Linda Mihalov serve on the Sonography Guided Transcervical Ablation of Uterine Fibroids study steering committee.
The authors thank David Toub, MD, MBA, Medical Director of Gynesonics, Inc, and Taraneh G. Farazi, PhD, Vice-President of Clinical Affairs at Gynesonics, for contributing to the preparation and review of the manuscript. QST Consultations, LTD provided biostatistical analysis for this study.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews are available at https://links.lww.com/AOG/B226.
